Resveratrol liposomes reverse sorafenib resistance in renal cell carcinoma models by modulating PI3K-AKT-mTOR and VHL-HIF signaling pathways

RCC is a malignant tumor arising from the urothelium of renal parenchyma that remains challenging to be treated. In this study, we assessed the anti-tumor effects of Resveratrol liposomes (RES-lips) combined with sorafenib on renal cell carcinoma (RCC) and explored the potential mechanisms underlyin...

Full description

Bibliographic Details

Published in:	International Journal of Pharmaceutics: X
Main Authors:	Ligang Wang, Ying Wang, Qiqi Xie, Songcheng Xu, Chen Yang, Fei Liu, Yang Liu, Fuwei Wang, Weinan Chen, Jianchun Li, Litao Sun
Format:	Article
Language:	English
Published:	Elsevier 2024-12-01
Subjects:	Resveratrol liposomes Sorafenib Resistance Combination Renal cell carcinoma PI3K-AKT-mTOR
Online Access:	http://www.sciencedirect.com/science/article/pii/S2590156724000525